Evidence map›Paper›PMID 25654651›Full record

ArticleeLife2015

The sheddase ADAM10 is a potent modulator of prion disease.

Hermann C Altmeppen, Johannes Prox, Susanne Krasemann, Berta Puig, Katharina Kruszewski, Frank Dohler, Christian Bernreuther, Ana Hoxha, Luise Linsenmeier, Beata Sikorska and 4 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. A Valuable Target for Therapy: The Metalloproteinase ADAM10.Current protein & peptide science · 2025
    Review
  6. Therapeutic Trajectories in Human Prion Diseases.Sub-cellular biochemistry · 2025
    Review
  7. Review
  8. Non-canonical function of ADAM10 in presynaptic plasticity.Cellular and molecular life sciences : CMLS · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Post-translational modifications in prion diseases.Frontiers in molecular neuroscience · 2024
    Review
  13. New implications for prion diseases therapy and prophylaxis.Frontiers in molecular neuroscience · 2024
    Review
  14. Review
  15. Diminished Neuronal ESCRT-0 Function Exacerbates AMPA Receptor Derangement and Accelerates Prion-Induced Neurodegeneration.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Prion Protein: The Molecule of Many Forms and Faces.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Hermann C AltmeppenInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johannes ProxInstitute of Biochemistry, Christian Albrechts University, Kiel, Germany.
Susanne KrasemannInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Berta PuigInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Katharina KruszewskiDepartment of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frank DohlerInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian BernreutherInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ana HoxhaInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Luise LinsenmeierInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Beata SikorskaDepartment of Molecular Pathology and Neuropathology, Medical University Lodz, Lodz, Poland.
Pawel P LiberskiDepartment of Molecular Pathology and Neuropathology, Medical University Lodz, Lodz, Poland.
Udo BartschDepartment of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Paul SaftigInstitute of Biochemistry, Christian Albrechts University, Kiel, Germany.
Markus GlatzelInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DEChristian-Albrechts-Universität zu Kiel · DEMedical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prion protein (PrP(C)) is highly expressed in the nervous system and critically involved in prion diseases where it misfolds into pathogenic PrP(Sc). Moreover, it has been suggested as a receptor mediating neurotoxicity in common neurodegenerative proteinopathies such as Alzheimer's disease. PrP(C) is shed at the plasma membrane by the metalloprotease ADAM10, yet the impact of this on prion disease remains enigmatic. Employing conditional knockout mice, we show that depletion of ADAM10 in forebrain neurons leads to posttranslational increase of PrP(C) levels. Upon prion infection of these mice, clinical, biochemical, and morphological data reveal that lack of ADAM10 significantly reduces incubation times and increases PrP(Sc) formation. In contrast, spatiotemporal analysis indicates that absence of shedding impairs spread of prion pathology. Our data support a dual role for ADAM10-mediated shedding and highlight the role of proteolytic processing in prion disease.

Indexed as

ADAM10 ProteinADAM ProteinsAmyloid Precursor Protein SecretasesAnimalsCalpainHumansMembrane ProteinsMiceMice, KnockoutPrion DiseasesProsencephalonPrPC ProteinsADAM10 ProteinADAM10 protein, humanADAM ProteinsAmyloid Precursor Protein SecretasesCalpainMembrane ProteinsPrPC ProteinsADAM10infectious diseasemicrobiologymouseneurodegenerationneuroscienceprion diseaseproteolytic processingshedding

Identifiers

PMID25654651
PMCPMC4346534
OpenAlexW1992535168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.